Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BAALC antisense RNA 1 (BAALC-AS1)
- Target
- BAALC-AS1
- Molecular classification
- Long non-coding RNA, Natural antisense transcript, Other (non-coding RNA)
01
Overview
BAALC antisense RNA 1 (BAALC-AS1) is a long non-coding RNA (lncRNA) located in the antisense strand of the BAALC gene region on chromosome 8q22.3[2]. It is also known as lncFZD6, FZD6-DT, FZD6 divergent transcript, or LOC105369147. BAALC-AS1 is upregulated in esophageal squamous cell carcinoma (ESCC) and plays an oncogenic role by promoting cell proliferation, migration, and invasion. Mechanistically, BAALC-AS1 directly binds to the protein G3BP2 and inhibits G3BP2-dependent degradation of c-Myc mRNA, leading to increased c-Myc expression. In turn, c-Myc upregulates BAALC-AS1 transcription, establishing a positive feedback loop. High BAALC-AS1 expression correlates with aggressive tumor phenotypes and is proposed as a potential therapeutic target and a biomarker for cancer diagnosis and prognosis, with particular emphasis in ESCC[1][2][3][4]. There are currently no approved drugs targeting BAALC-AS1.
- Other names
- lncFZD6FZD6-DTFZD6 divergent transcriptLOC105369147
02
Mechanism of action
No known approved drugs directly targeting BAALC-AS1. Experimental evidence: silencing BAALC-AS1 suppresses c-Myc signaling, reduces proliferation and invasion in ESCC cells[1][2][3][4]
03
Biological functions
Regulation of gene expressionPromotion of cell proliferationPromotion of cell migrationPromotion of cell invasionPositive regulation of c-Myc expression
04
Disease associations
CancerEsophageal squamous cell carcinoma (ESCC)Potential role in other malignancies (pending further validation)
05
Safety considerations
No established safety concerns, as clinical targeting is preclinical; potential safety issues would relate to general targeting of non-coding RNAs and interfering with c-Myc regulation
06
Biomarkers
Overexpression of BAALC-AS1 as a biomarker for ESCC malignancy and prognosis[1][2][3][4]
Beyond the preview
Go deeper on BAALC antisense RNA 1 (BAALC-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BAALC antisense RNA 1 (BAALC-AS1).